Episode 64: Feuding professors, failing businesses, and journalism 101
Who's guilty of "clickbait"? Are spit tubes a bad business? And why are academics emulating Pusha T?
30 Mai 201923min
Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer
What should you watch for at the year's biggest cancer conference? Why are people having 23andMe-induced identity crises? And what's it like to be at once a journalist and a cancer patient?
23 Mai 201931min
Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials
Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for that?
16 Mai 201923min
Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA
Are law-breaking pharma executives the new mob bosses? Can genome editing preventing heart attacks? And can the FDA regulate drug prices?
9 Mai 201925min
Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms
Is Biogen bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will "micro-dosing" light the way to actual therapies?
2 Mai 201922min
Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup
Who gets to be "influential"? Should you be skeptical of for-profit hospitals? And should George Lucas fire his attorneys?
25 Apr 201922min
Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print
Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?
18 Apr 201921min
Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst
How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?
11 Apr 201925min
